Endothelin-1 research: ETA/ETB signaling, trafficking, and assay design

1) Define the ET-1 system before choosing a readout

Yanagisawa and colleagues isolated endothelin from endothelial-cell culture medium as a 21-residue peptide and cloned its precursor in 1988.^[1] Mature ET-1 contains two intramolecular disulfide bonds, so sequence, oxidation state, and terminal chemistry are all part of reagent identity. “Endothelin” is not a sufficient methods description: the endogenous family includes ET-1, ET-2, and ET-3, and related sarafotoxins are frequently used as pharmacological probes.

Two class A GPCR subtypes mediate endothelin responses. Human ETA is encoded by EDNRA; human ETB is encoded by EDNRB. Cloning studies established that the receptors are distinct proteins rather than interchangeable states of one receptor.^[2,3] In recombinant systems, ET-1 can bind both at high affinity, whereas ET-3 and sarafotoxin S6c provide useful subtype discrimination under qualified conditions. Receptor expression must therefore be measured rather than inferred from tissue name.

Record peptide sequence, disulfide status, counterion, net peptide content, analytical purity, lot, solvent, vessel material, storage interval, and freeze–thaw history. For receptor constructs, report species, accession, tag position, mutations, promoter, clone or pool, and quantitative surface abundance. Those details prevent a receptor-expression artifact from being mistaken for ligand selectivity.

2) ET-1 recognition is distributed across a constrained peptide

The disulfide framework holds ET-1 in a compact fold while its C-terminal segment enters deeply into the receptor pocket. Recent cryo-EM structures captured ET-1 with ETA–Gq and ETB–Gq complexes and resolved a shared recognition logic across the two receptors.^[4] The structures also show why small sequence changes can affect receptor subtype preference: affinity is created by a network of contacts rather than a single universal “active motif.”

Structural information should guide, not replace, functional testing. Truncation, alanine substitution, disulfide removal, oxidation, labeling, or conjugation may alter binding, efficacy, proteolytic stability, and adsorption simultaneously. Compare each analog with the intact native peptide in the same assay, run full concentration-response curves, and measure actual peptide recovery when chemistry changes.

Radioligand experiments in cloned human receptors found picomolar ET-1 binding and clearly different competition profiles for ETA and ETB.^[5] Binding affinity does not specify signaling efficacy, however. Equilibrium assumptions are especially risky when a ligand–receptor complex dissociates slowly. Association, dissociation, temperature, wash duration, membrane protein, and nonspecific binding should be reported explicitly.

3) Pair calcium with a proximal receptor test

ETA and ETB commonly couple to Gq/11, activating phospholipase C, generating inositol phosphates, mobilizing intracellular calcium, and engaging protein kinase C. Both receptors can also couple to other G proteins depending on cell background and receptor abundance. A calcium transient is therefore a sensitive operational readout, not a unique molecular signature of either subtype.

Design calcium experiments around kinetics. Report dye or sensor, loading conditions, extracellular calcium, acquisition frequency, baseline window, addition timing, peak and area metrics, and normalization. Include vehicle, parental or receptor-null cells, and a detector-competence control. If endogenous purinergic, adrenergic, or other Gq receptors are present, subtype-selective pharmacology alone is weaker evidence than genetic receptor loss plus rescue.

Use an orthogonal proximal assay when the conclusion depends on pathway identity: direct G-protein activation, IP1 accumulation, DAG production, or a validated biosensor can support the calcium result. ERK phosphorylation, transcription, proliferation, contraction, or morphology integrate multiple pathways and time points. Those endpoints require receptor dependence and a proximal link before being labeled “ETA signaling” or “ETB signaling.”

Run complete curves with independent biological replicates. Report maximal response, potency with uncertainty, Hill slope or fit constraints, raw baseline, and replicate hierarchy. A single concentration cannot distinguish affinity, efficacy, amplification, or exposure loss.

4) ETA and ETB diverge after a shared internalization step

Time is mechanistically informative in this system. In transfected cells, both receptor subtypes underwent arrestin- and dynamin/clathrin-dependent internalization after endothelin stimulation, but their subsequent routes differed: ETA preferentially entered a recycling pathway, while ETB was directed toward lysosomes.^[6] This makes a single endpoint inadequate for comparing sustained signaling or receptor recovery.

A trafficking experiment should measure starting surface receptor, ligand-induced surface loss, total receptor, endosomal localization, degradation, and surface recovery after validated washout. Early endosome colocalization is not proof of recycling or destruction. Use time-resolved markers and quantify compartments with blinded thresholds. Tagged receptors require benchmarking against untagged receptors for binding, signaling, and internalization.

Strong ligand retention can complicate washout. Test functional recovery rather than assuming that bulk medium exchange removed receptor-bound ET-1. Acid wash, competitive displacement, or extended washout may perturb cells and must be validated independently. Apparent receptor desensitization can reflect persistent occupancy, depleted calcium stores, reporter adaptation, or true receptor regulation.

5) Nominal ET-1 concentration is not measured exposure

ET-1 can be lost through adsorption, repeated transfers, matrix binding, proteolysis, or redox damage. Low-concentration stocks are particularly vulnerable to surface loss. Standardize vessel material, carrier, pH, ionic strength, transfer count, temperature, incubation matrix, and delay before addition. Prepare the dilution series with matched dwell times and avoid comparing fresh and aged dilutions as though they were equivalent.

When stability is central to the conclusion, qualify an LC–MS or chromatographic method that resolves intact ET-1 from fragments and altered disulfide species. Total immunoreactivity or fluorescence may persist after the active chemical form has changed. Include fresh standards, matrix-spiked recovery, time-matched peptide without cells, and extraction controls.

Fluorescent and radiolabeled ET-1 probes are valuable for binding and trafficking, but the label may change charge, hydrophobicity, receptor kinetics, or degradation. Establish the modified probe’s competition and functional curves against unlabeled ET-1. Separate total association from surface binding and internalized signal with a validated method.

6) Receptor context determines apparent subtype pharmacology

Heterologous cells give clean receptor identity but can create receptor reserve, altered G-protein coupling, and nonphysiological trafficking. Match ETA and ETB surface expression when comparing potency or efficacy. A parental line, receptor-null derivative, and rescue construct form a stronger attribution set than antagonism alone.

Native endothelial, smooth-muscle, neural, or stromal models preserve relevant signaling machinery but often express both receptors plus ligand-processing enzymes. Quantify EDNRA and EDNRB transcripts and surface protein, then combine selective ligands with genetic perturbation. Transcript detection alone does not demonstrate a functional surface receptor.

For subtype claims, run matched counterscreens. ET-1 is not an ETA-only probe. ET-3 and sarafotoxin S6c can help characterize ETB, while BQ-123-class ligands can help interrogate ETA, but selectivity depends on concentration, species, assay, and exposure time. Use a range that preserves the known selectivity window and verify off-target effects in receptor-null cells.

7) A reproducible endothelin-1 laboratory workflow

1. Specify the ligand. Record sequence, disulfides, counterion, content, purity, lot, solvent, and handling history.
2. Qualify the model. Measure ETA and ETB surface expression and document relevant endogenous receptors.
3. Pilot kinetics. Map binding, calcium onset, adaptation, internalization, washout, and recovery before fixing endpoints.
4. Run full curves. Include vehicle, receptor-null, detector-only, and viability controls.
5. Resolve subtype and pathway. Combine genetic attribution with matched proximal assays and qualified pharmacology.
6. Control exposure. Standardize matrix and vessels; measure intact ET-1 when stability can change interpretation.
7. Study trafficking separately. Quantify surface loss, compartment entry, degradation, and recovery rather than relying on puncta.
8. Predefine analysis. State normalization, curve model, kinetic metrics, exclusions, replicate hierarchy, and statistical tests.

8) Evidence limits and common errors

• Do not treat ET-1 as ETA-selective. It can activate both receptor subtypes.
• Do not assign subtype from calcium, ERK, contraction, or morphology alone. Require receptor dependence.
• Do not compare receptor subtypes without matching surface abundance. Receptor reserve can mimic pharmacological differences.
• Do not infer recycling or degradation from static colocalization. Measure time-resolved receptor fate and recovery.
• Do not assume washout removes tightly retained ligand. Validate functional de-occupancy.
• Do not equate nominal concentration with intact exposure. Measure recovery when chemistry is consequential.
• Do not extrapolate cell or animal findings into self-use, treatment, performance, or anti-aging claims. Conclusions remain limited to the tested system.

A rigorous ET-1 experiment links a chemically defined, disulfide-intact peptide to measured ETA or ETB surface expression, a proximal kinetic readout, controlled exposure, receptor-subtype counterscreens, and time-resolved trafficking. That chain separates receptor pharmacology from peptide loss, pathway convergence, persistent occupancy, and reporter behavior.